Proteomic diagnosis of Sjögren's syndrome

Expert Review of Proteomics

Volumn 4, Issue 6, 2007, Pages 757-767

  Giusti, Laura ^a   Baldini, Chiara ^a   Bazzichi, Laura ^a   Bombardieri, Stefano ^a   Lucacchini, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

2DE; Mass spectrometry; Proteomics; Rheumatic disease; Saliva; Salivary glands; Sj gren's syndrome; Tear

Indexed keywords

SALIVA PROTEIN; TEAR PROTEIN;

AMINO ACID SEQUENCE; DIAGNOSTIC TEST; ELECTROSPRAY MASS SPECTROMETRY; EPIGENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PAROTID GLAND; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SALIVARY GLAND; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; HUMANS; LACRIMAL APPARATUS; PAROTID GLAND; PROTEOMICS; RHEUMATOLOGY; SALIVA; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 37149034761     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.6.757     Document Type: Review

References (86)

1. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann. Rheum. Dis. 64, 347-354 (2005).
2. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren's syndrome. Arch. Intern. Med. 164, 1275-1284 (2004).
3. Youinou P, Daridon C, Saraux A, Devauchelle V, Pers JO. Is B-cell the conductor of the lymphocyte orchestra in the salivary glands of patients with primary Sjögren's syndrome? Clin. Exp. Rheumatol. 24, 491-492 (2006).
4. Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A. Epidemiology of Sjögren's syndrome: where are we now? Clin. Exp. Rheumatol. 25, 1-4 (2007).
5. Fox RI. Sjögren's syndrome. Lancet 366, 321-331 (2005).
6. Vitali C, Bombardieri S, Jonsson R et al. European Study Group on classification criteria for Sjögren's syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61, 554-558 (2002). • Original publication of the revised American and European classification criteria for Sjögren's syndrome.
7. Gran JT. Diagnosis and definition of primary Sjögren's syndrome. Scand. J. Rheumatol. 31, 57-59 (2002).
8. Hay EM, Thomas E, Pal B, Hajer A, Chambers H, Silman AJ. Weak association between subjective symptoms and objective testing for dry eyes and mouth: results from a population based study. Ann. Rheum. Dis. 57, 20-24 (1998).
9. Manganelli P, Fietta P, Quaini F. Hematologic manifestations of primary Sjögren's syndrome. Clin. Exp. Rheumatol. 24, 438-448 (2006).
10. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's Syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum. 42, 1765-1772 (1999).
11. Hermansson M, Sawaji Y, Bolton M et al. Proteomic analysis of articular cartilage shows increased type II collagen synthesis in osteoarthritis and expression of inhibin βA (activin A), a regulatory molecule for chondrocytes. J. Biol. Chem. 279, 43514-43521 (2004).
12. De Ceuninck F, Marcheteau E, Berger S et al. Assessment of some tools for the characterization of the human osteoarthritic cartilage proteome. J. Biomol. Tech. 16, 256-265 (2005).
13. Ruiz-Romero C, Lopez-Armada MJ, Blanco FJ. Proteomic characterization of human normal articular chondrocytes: a novel tool for the study of osteoarthritis and other rheumatic diseases. Proteomics 5, 3048-3059 (2005).
14. Sinz A, Bantscheff M, Mikkat S et al. Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 23, 3445-3456 (2002).
15. Liao H, Wu J, Kuhn E et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 50, 3792-3803 (2004).
16. Drynda S, Ringel B, Kekow M et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFα therapy. Pathol. Res. Pract. 200, 165-171 (2004).
17. de Seny D, Fillet M, Meuwis MA et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 52, 3801-3812 (2005).
18. An Y, Pu H, He SZ, Li ZG. Identification of biomarkers in serum of early rheumatoid arthritis by proteomic methods. Zhonghua Yi Xue Za Zhi 85, 1261-1265 (2005).
19. Tilleman K, Van Beneden K, Dhondt A et al. Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics 5, 2247-2257 (2005).
20. Hueber W, Kidd BA, Tomooka BH et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum. 52, 2645-2655 (2005).
21. Kim CW, Cho EH, Lee YJ, Kim YH, Hah YS, Kim DR. Disease-specific proteins from rheumatoid arthritis patients. J. Korean Med. Sci. 21, 478-484 (2006).
22. Matsuo K, Xiang Y, Nakamura H et al. Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res. Ther. 8, R175 (2006).
23. Hueber W, Tomooka BH, Zhao X et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann. Rheum. Dis. 66, 712-719 (2007).
24. Roy SM, Becker CH. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling. Methods Mol. Biol. 359, 87-105 (2007).
25. Stone JH, Rajapakse VN, Hoffman GS III et al. Wegener's granulomatosis Etanercept Trial Research Group. A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis Rheum. 52, 902-910 (2005).
26. Fietta A, Bardoni A, Salvini R et al. Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res. Ther. 8, R160 (2006).
27. Giusti L, Bazzichi L, Baldini C et al. Specific proteins identified in human whole saliva from diffuse systemic sclerosis patients. J. Rheumatol. (2007) (In Press).
28. Xiang Y, Matsui T, Matsuo K et al. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. Arthritis Rheum. 56, 2018-2030 (2007).
29. Häupl T, Krenn V, Stuhlmüller B, Radbruch A, Burmester GR. Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies. Arthritis Res. Ther. 6, 140-146 (2004).
30. Patterson SD. Proteomics: beginning to realise its promise?. Arthritis Rheum. 50, 3741-3744 (2004).
31. Ali M, Manolios N. Proteomics in rheumatology: a new direction for old diseases. Sem. Arthritis Rheum. 35, 67-76 (2005).
32. Tilleman K, Deforce D, Elewaut D. Rheumatology: a close encounter with proteomics. Rheumatology 44, 1217-1226 (2005).
33. Wu T, Mohan C. Proteomics on the diagnostic horizon: lessons from rheumatology. Am. J. Med. Sci. 333, 16-25 (2007).
34. O'Farrel PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 250, 4007-4021 (1975).
35. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4, 3665-3685 (2004).
36. Delahunty C, Yates JR III. Protein identification using 2D-LC-MS/MS. Methods 35, 248-255 (2005).
37. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422, 198-207 (2003).
38. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 246, 64-71 (1989).
39. Kislinger T, Emili A. Multidimensional protein identification technology: current status and future prospects. Expert Rev. Proteomics 2, 27-39 (2005).
40. Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol. Res. Pract. 200, 83-94 (2004).
41. Avisar R, Menaché R, Shaked P, Rubinstein J, Machtey I, Savir H. Lysozyme content of tears in patients with Sjögren's syndrome and rheumatoid arthritis. Am. J. Ophthalmol. 87, 148-151 (1979).
42. Janssen PT, van Bijsterveld OP. Tear fluid proteins in Sjögren's syndrome. Scand. J. Rheumatol. Suppl. 61(Suppl.), 224-227 (1986).
43. Berta A, Török M. Tear glycoprotein determinations in the diagnosis and differential diagnosis of dry eyes. Scand. J. Rheumatol. 61(Suppl.) 228-233 (1986).
44. Suárez JC. Lacrymal proteins in Sjögren's syndrome. Ophthalmologica 194, 188-190 (1987).
45. Boukes RJ, Boonstra A, Breebaart AC et al. Analysis of human tear protein profiles using high performance liquid chromatography (HPLC). Doc. Ophthalmol. 67, 105-113 (1987).
46. van Bijsterveld OP, Mackor AJ. Sjögren's syndrome and tear function parameters. Clin. Exp. Rheumatol. 7, 151-154 (1989).
47. Markusse HM, Huysen JC, Nieuwenhuys EJ, Swaak AJ. ?2 microglobulin in tear fluid from patients with primary Sjögren's syndrome. Ann. Rheum. Dis. 51, 503-505 (1992).
48. Markusse HM, van Haeringen NJ, Swaak AJ, Hogeweg M, de Jong PT. Tear fluid analysis in primary Sjögren's syndrome. Clin. Exp. Rheumatol. 11, 175-178 (1993).
49. Ono M, Yoshino K, Tsubota K, Saito I. Subclass expression of IgA in lacrymal glands of patients with Sjögren's syndrome Adv. Exp. Med. Biol. 350, 185-188 (1994).
50. Bjerrum KB. The ratio of albumin to lactoferrin in tear fluid as a diagnostic tool in primary Sjögren's syndrome. Acta Ophthalmol. Scand. 75, 507-511 (1997).
51. Bjerrum KB. Tear fluid analysis in patients with primary Sjögren's syndrome using lectin probes. A comparative study of patients with primary Sjögren's syndrome, patients with other immune inflammatory connective tissue diseases and controls. Acta Ophthalmol. Scand. 77, 1-8 (1999).
52. Grus FH, Augustin AJ. Protein analysis methods in diagnosis of sicca syndrome. Ophthalmologe 97, 54-61 (2000).
53. Cojocaru VM, Ciurtin C, Puchianu E, Antohe F. Lacrimal proteins electrophoretic analysis - diagnostic method in secondary Sjögren's syndrome. Oftalmologia 50, 60-63 (2006).
54. Talal N, Grey HM, Zvaifler N, Michalski JP, Daniels TE. Elevated salivary and synovial fluid β2-microglobulin in Sjögren's syndrome and rheumatoid arthritis. Science 187, 1196-1198 (1975).
55. Michalski JP, Daniels TE, Talal N, Grey HM. β2 microglobulin and lymphocytic infiltration in Sjögren's syndrome. N. Engl. J. Med. 293, 1228-1231 (1975).
56. Mandel ID, Baurmash H. Sialochemistry in Sjögren's syndrome. Oral Surg. Oral Med. Oral Pathol. 41, 182-187 (1976).
57. Tabak L, Mandel ID, Karlan D, Baurmash H. Alterations in lactoferrin in salivary gland disease. J. Dent. Res. 57, 43-47 (1978).
58. Ghozlan R, Amor B, Mach PS, Delbarre F. Variations in salivary immunoglobulins in Sjögren's syndrome. Rev. Stomatol. Chir. Maxillofac. 79, 113-117 (1978).
59. Moutsopoulos HM, Karsh J, Wolf RO, Tarpley TM, Tylenda A, Papadopoulos NM. Lysozyme determination in parotid saliva from patients with Sjögren's syndrome. Am. J. Med. 69, 39-42 (1980).
60. Pennec Y, Ferrec C, Youinou P et al. Salivary lysozyme, immunoglobulins and β2-microglobulin in Gougerot-Sjögren syndrome. Nouv. Presse Med. 11, 3481-3484 (1982).
61. Stuchell RN, Mandel ID, Baurmash H. Clinical utilization of sialochemistry in Sjögren's syndrome. J. Oral Pathol. 13, 303-309 (1984).
62. Tsianos EB, Tzioufas AG, Mavridis AK et al. Sialochemistry of patients with autoimmune rheumatic disease with and without histological manifestations of Sjögren's syndrome. Ann. Rheum. Dis. 44, 412-414 (1985).
63. Fox PC, Sarras AK, Bowers MR, Drosos AA, Moutsopoulos HM. Oral and sialochemical findings in patients with autoimmune rheumatic disease. Clin. Exp. Rheumatol. 5, 123-126 (1987).
64. Friberg B, Jonsson R, Linde A. Salivary kallikrein in Sjögren's syndrome. Clin. Exp. Rheumatol. 6, 135-138 (1988).
65. Jezequel N, Depasse F, Jouquan J et al. Salivary lactoferrin in primary Sjögren's syndrome. Clin. Exp. Rheumatol. 7, 123-125 (1989).
66. Bianucci G, Campana G, Bongi SM, Palermo C, D'Agata A. Salivary and serum β2-microglobulin in the diagnosis of primary Sjögren's syndrome. Minerva Med. 83, 705-713 (1992).
67. Markusse HM, Otten HG, Vroom TM, Smeets TJ, Fokkens N, Breedveld FC. The diagnostic value of salivary fluid levels of β2-microglobulin, lysozyme and lactoferrin for primary Sjögren's syndrome. Clin. Rheumatol. 11, 521-525 (1992).
68. van der Geest SA, Markusse HM, Swaak AJ. β2 microglobulin measurements in saliva of patients with primary Sjögren's syndrome: influence of flow. Ann. Rheum. Dis. 52, 461-463 (1993).
69. Mogi M, Kage T, Chino T, Yoshitake K, Harada M. Increased β2-microglobulin in both parotid and submandibular/sublingual saliva from patients with Sjögren's syndrome. Arch. Oral Biol. 39, 913-915 (1994).
70. Maddali Bongi S, Campana G, D'Agata A, Palermo C, Bianucci G. The diagnosis value of β2-microglobulin and immunoglobulins in primary Sjögren's syndrome. Clin. Rheumatol. 14, 151-156 (1995).
71. van der Reijden WA, van der Kwaak JS, Veerman EC, Nieuw Amerongen AV. Analysis of the concentration and output of whole salivary constituents in patients with Sjögren's syndrome. Eur. J. Oral Sci. 104, 335-340 (1996).
72. Carpenter GH, Proctor GB, Pankhurst CL, O'Donohue J, Scott D, Hunnable MP. Sialochemical markers of salivary gland involvement with Sjögren's syndrome secondary to rheumatoid arthritis and primary biliary cirrhosis. J. Oral Pathol. Med. 29, 452-459 (2000).
73. Almstähl A, Wikström M, Groenink J. Lactoferrin, amylase and mucin MUC5B and their relation to the oral microflora in hyposalivation of different origins. Oral Microbiol. Immunol. 16, 345-352 (2001).
74. Sistig S, Vucicevic-Boras V, Lukac J, Kusic Z. Salivary IgA and IgG subclasses in oral mucosal diseases. Oral Dis. 8, 282-286 (2002).
75. Haghighat N, Al-Hashimi I. The status of lactoferrin and total iron binding capacity of human parotid saliva in Sjögren's syndrome. Clin. Exp. Rheumatol. 21, 485-488 (2003).
76. Eliasson L, Almstähl A, Lingström P, Wikström M, Carlén A. Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjögren's syndrome and radiation therapy. Arch. Oral Biol. 50, 293-299 (2005).
77. Deming FP, Al-Hashimi I, Haghighat N et al. Comparison of salivary calmodulin binding proteins in Sjögren's syndrome and healthy individuals. J. Oral Pathol. Med. 36, 132-135 (2007).
78. Beeley JA, Khoo KS. Salivary proteins in rheumatoid arthritis and Sjögren's syndrome: one-dimensional and two-dimensional electrophoretic studies. Electrophoresis 20, 1652-1660 (1999).
79. Tomosugi N, Kitagawa K, Takahashi N, Sugai S, Ishikawa I. Diagnostic potential of tear proteomic patterns in Sjögren's syndrome J. Proteome Res. 4, 820-825 (2005). • First published study using SELDI-TOF to investigate the tear protein expression pattern in primary Sjögren's syndrome (pSS).
80. Ryu OH, Atkinson JC, Hoehn GT, Illei GG, Hart TC. Identification of parotid salivary biomarkers in Sjögren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology 45, 1077-1086 (2006). • First published study using 2D difference gel electrophoresis and SELDI-TOF to investigate parotid saliva protein expression pattern in pSS.
81. Giusti L, Baldini C, Bazzichi L et al. Proteome analysis of whole saliva: a new tool for rheumatic diseases - the example of Sjögren's syndrome. Proteomics 7, 1634-1643 (2007). • First published study using 2DE-MALDI-TOF to investigate whole saliva protein expression pattern in pSS.
82. Stea EA, Routsias JG, Samiotaki M et al. Analysis of parotid glands of primary Sjögren's syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets. Clin. Exp. Immunol. 147, 81-89 (2007). • Investigated modifications of known autoantigens and determine new targets of the autoimmune response in the parotid glands of pSS patients.
83. Peluso G, De Santis M, Inzitari C et al. Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum. 56, 2216-2222 (2007). • Investigated the effect of pilocarpine on the salivary peptide and protein profile in patients with pSS.
84. Amado FM, Vitorino RM, Domingues PM, Lobo MJ, Duarte JA. Analysis of the human saliva proteome. Expert Rev. Proteomics 2, 521-539 (2005). • Extensive review of state-of-the-art methodologies applied to the analysis of salivary proteins with special emphasis on human saliva composition.
85. Horsfall AC, Rose LM, Maini RN. Autoantibody synthesis in salivary glands of Sjögren's syndrome patients. J. Autoimmun. 2, 559-566 (1989).
86. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics 4, 51-65 (2007).